China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Accumulated Expenses for 9 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses rose 12.49% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 12.49% YoY) and the FY2026 annual result came in at $3.3 million, up 12.49% from the prior year.
• Accumulated Expenses advanced to $3.3 million in Q1 2026 per SXTC's latest filing, from $3.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for SXTC reached as high as $3.5 million in Q1 2022 and fell as low as $2.8 million in Q1 2024.
• A 5-year average of $3.2 million and a median of $3.2 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses gained 15.84% — and 2024, when it declined 11.89%.
• Year by year, Accumulated Expenses stood at $3.3 million in 2022, then fell by 0.89% to $3.2 million in 2023, then dropped by 10.05% to $2.9 million in 2024, then climbed by 11.77% to $3.3 million in 2025, then gained by 1.17% to $3.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.3 million, $3.3 million, and $2.9 million for Q1 2026, Q3 2025, and Q1 2025 respectively.